Pesquisar
Ultragenyx Pharmaceutical Inc
RAREAdicionar à lista de desejos
32.860USD
-0.530-1.59%
Horário de mercado （ET）Cotações atrasadas em 15 min
3.23BValor de mercado
PerdaP/L TTM
Mais detalhes de Ultragenyx Pharmaceutical Inc Empresa
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Informações de Ultragenyx Pharmaceutical Inc
Código da empresaRARE
Nome da EmpresaUltragenyx Pharmaceutical Inc
Data de listagemJan 31, 2014
CEOKakkis (Emil D)
Número de funcionários1294
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 31
Endereço60 Leveroni Ct
CidadeNOVATO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94949
Telefone14154838800
Sitehttps://www.ultragenyx.com/
Código da empresaRARE
Data de listagemJan 31, 2014
CEOKakkis (Emil D)
Executivos da empresa Ultragenyx Pharmaceutical Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
140.45K
+16.46%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
44.07K
-10.56%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
34.70K
+22.34%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
34.70K
+22.34%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
25.38K
+30.54%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
22.21K
+9.05%
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
140.45K
+16.46%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
44.07K
-10.56%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
34.70K
+22.34%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
34.70K
+22.34%
Perguntas frequentes
Quem são os cinco principais acionistas de Ultragenyx Pharmaceutical Inc?
Os cinco principais acionistas de Ultragenyx Pharmaceutical Inc são: Dr. Emil D. Kakkis, M.D., Ph.D.
Quantas instituições possuem ações da Ultragenyx Pharmaceutical Inc (RARE)?
Em 2026Q1, 695 instituições possuíam ações da Ultragenyx Pharmaceutical Inc, com valor de mercado aproximado de 106.19M, representando 107.82% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1315399.00.
Qual é a maior fonte de receita da Ultragenyx Pharmaceutical Inc?
Em 2026Q1, o segmento de negócios Crysvita royalty revenue gerou a maior receita para Ultragenyx Pharmaceutical Inc, totalizando 304.00M e representando 45.17% da receita total.